Buenos Aires, C1406DGI, Argentina
NCT Number: NCT00830648
Safety of a Second Dose of Biken's Varicella Vaccine
The objective of the present study is to assess and document the safety of a second dose of Varicella Biken vaccine administered at 4 to 6 years of age in healthy children having previously received a first dose of Varicella Biken vaccine.
All subjects will receive a second dose of Varicella vaccine (Varicella Biken) at 4 to 6 years of age.
The expected total duration of follow-up (first visit to last visit) for each subject will be one month.
Looking for future studies?
Notify MeKey information
Conditions
Age range
4 year–6 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 4
Primary location
Who can participate
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- Aged 4 to 6 years on the day of inclusion.
- Informed consent form signed by the parent(s) or legal guardian and by an independent witness.
- Subject and parent/guardian able to attend all scheduled visits and comply with all trial procedures.
- Written documentation of receipt of a first dose of Varicella Biken vaccine more than 3 months before inclusion.
Exclusion criteria
- Participation in another clinical trial investigating a vaccine, drug, medical device, or a medical procedure in the 4 weeks preceding the trial vaccination.
- Planned participation in another clinical trial during the present trial period.
- Known or suspected congenital or acquired immunodeficiency, immunosuppressive therapy such as anti-cancer chemotherapy or radiation therapy within the preceding 6 months, or long-term systemic corticosteroids therapy.
- Known systemic hypersensitivity to any of the vaccine components or history of a life-threatening reaction to the trial vaccine or to a vaccine containing any of the same substances.
- Chronic illness, at a stage that could interfere with trial conduct or completion, in the opinion of the investigator.
- Receipt of any vaccine in the 4 weeks preceding the trial vaccination;
- Planned receipt of any vaccine in the 4 weeks following the trial vaccination.
- Known Human Immunodeficiency Virus (HIV), Hepatitis B surface antigen, or Hepatitis C seropositivity.
- History of varicella infection (confirmed either clinically, serologically or microbiologically).
- Previous vaccination against varicella disease with a vaccine different from Varicella Biken vaccine.
- Febrile illness (temperature ≥ 37.5°C) or moderate or severe acute illness/infection on the day of vaccination, according to investigator judgment.
Treatment and study plan
Live Attenuated Varicella Virus Vaccine
Biological0.5 mL, Subcutaneous
Other names: Varicela Biken
Primary outcomes
-
To provide information concerning the safety after administration of Varicella vaccine
Time frame: one month after vaccination
Sponsors and collaborators
Lead sponsor
Sanofi Pasteur, a Sanofi Company
Industry
Registry information
Official study title
Safety of a Second Dose of Biken's Varicella Vaccine Administered at 4 to 6 Years of Age in Healthy Children in Argentina
Important dates
- Study start
- 2009
- Primary completion
- 2009
- Study completion
- 2009
- First posted
- Jan 28, 2009
- Registry last updated
- Jun 10, 2013
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
Simultaneous Administration Study of Varicella Attenuated Live Vaccine and Trivalent Inactivated Influenza Vaccine (Split Virion)
NCT06987942
Chickenpox, DNA Virus Infections
Nanjing, Jiangsu, China
View Trial DetailsImmunogenicity and Safety of Varicella Vaccine, Live in Healthy Children Aged 12~15 Months in the Philippines
NCT06314724
Chickenpox, DNA Virus Infections
Pasay, Philippines
View Trial DetailsSafety and Immunogenicity of Live Attenuated Varicella Vaccine in Healthy Population Aged ≥13 Years Old
NCT05158777
Chickenpox, DNA Virus Infections
Zhenzhou, Henan, China
View Trial DetailsA Study of Combined Immunization With Live Attenuated Varicella Vaccine and Inactivated Hepatitis A Vaccine
NCT05526820
Chickenpox, DNA Virus Infections
Tai’an, Shandong, China
View Trial Details